Calamos Advisors’s Integra LifeSciences IART Stock Holding History

Calamos Advisors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,171	Closed	-$284K	–	1101
2026 Q1	$284K	Buy	+30,171	New	+$331K	﹤0.01%	1042

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Calamos Advisors's IART Position: Q2 2026 in Review

Calamos Advisors sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 30,171 shares — an estimated $284K sold.

Calamos Advisors first reported a position in IART in Q1 2026 and held it in 1 quarter. The position peaked at $284K in Q1 2026. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Calamos Advisors reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
Calamos Advisors sold 30,171 Integra LifeSciences shares in Q2 2026, an estimated $284K.
Calamos Advisors first reported a position in Integra LifeSciences in Q1 2026 and held it in 1 quarter.
Calamos Advisors's Integra LifeSciences position peaked at $284K in Q1 2026.
213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.